SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report)'s share price traded up 1.6% during trading on Wednesday . The company traded as high as $1.38 and last traded at $1.31. 1,674,518 shares traded hands during trading, an increase of 23% from the average session volume of 1,365,601 shares. The stock had previously closed at $1.29.
SELLAS Life Sciences Group Stock Up 1.4 %
The firm has a market capitalization of $129.91 million, a price-to-earnings ratio of -2.07 and a beta of 2.53. The stock has a 50-day moving average price of $1.19 and a 200 day moving average price of $1.16.
SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last announced its quarterly earnings results on Thursday, March 20th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.11) by $0.03. During the same period last year, the company earned ($1.34) earnings per share. As a group, equities analysts forecast that SELLAS Life Sciences Group, Inc. will post -0.57 earnings per share for the current fiscal year.
Hedge Funds Weigh In On SELLAS Life Sciences Group
A number of institutional investors and hedge funds have recently added to or reduced their stakes in SLS. Brooklyn FI LLC acquired a new stake in shares of SELLAS Life Sciences Group in the fourth quarter valued at approximately $677,000. Anson Funds Management LP boosted its holdings in shares of SELLAS Life Sciences Group by 50.2% in the fourth quarter. Anson Funds Management LP now owns 1,192,266 shares of the company's stock valued at $1,240,000 after acquiring an additional 398,431 shares during the period. Geode Capital Management LLC boosted its holdings in shares of SELLAS Life Sciences Group by 21.2% in the fourth quarter. Geode Capital Management LLC now owns 733,546 shares of the company's stock valued at $763,000 after acquiring an additional 128,355 shares during the period. State Street Corp boosted its holdings in shares of SELLAS Life Sciences Group by 30.2% in the third quarter. State Street Corp now owns 174,529 shares of the company's stock valued at $218,000 after acquiring an additional 40,500 shares during the period. Finally, Northern Trust Corp boosted its holdings in shares of SELLAS Life Sciences Group by 33.6% in the fourth quarter. Northern Trust Corp now owns 134,721 shares of the company's stock valued at $140,000 after acquiring an additional 33,878 shares during the period. 17.38% of the stock is owned by institutional investors and hedge funds.
SELLAS Life Sciences Group Company Profile
(
Get Free Report)
SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.
See Also
Before you consider SELLAS Life Sciences Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SELLAS Life Sciences Group wasn't on the list.
While SELLAS Life Sciences Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
